A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults

NCT00981175 | Completed Phase 2 Results DMC

• 1 other identifier: H-040-005
• Study Type: interventional
• Target: 202
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to assess the safety, tolerability, immunogenicity, and duration of immunity of one or two doses of ChimeriVax™-JE vaccine separated by 5 or 6 months in adults. Objectives: Safety:

• Obtain safety and tolerability data of a single, fixed dose of ChimeriVax™-JE compared with a placebo in adult volunteers (≥ 18 to \<55 years) without prior Japanese encephalitis (JE) vaccination. Immunogenicity:
• Obtain data on the antibody response in adult volunteers following administration of ChimeriVax™-JE
• Assess the durability of the immune response in adult volunteers over 60 months following one or two doses of ChimeriVax™-JE.

Conditions

Encephalitis; Japanese Encephalitis

Keywords

Japanese Encephalitis; Japanese Encephalitis Vaccines; Adult

Outcome Measures

Primary Outcomes (2)

• Number of Participants With Seroconversion to Homologous ChimeriVax-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Dose

  Assay by 50% Plaque Reduction Neutralization Test (PRNT50) Seroconversion: PRNT50 ≥ 10 and PRNT50 ≥ 20. Assessed in all participants who received ChimeriVax™-JE vaccine on Day 0 and Day 28.

  Day 28 post-vaccination

• Number of Participants Reporting Injection Site Treatment Emergent Adverse Events Post-Vaccination With ChimeriVax™-JE or Placebo at Day 0 and Day 28, and Following a Booster of ChimeriVax™-JE at Month 6 in a Subset of the Study Population.

  Injection Site Treatment Emergent Adverse Events: Pain, Reaction Not Otherwise Specified (NOS), Erythema, Swelling, Bruising, Nodule, Pigmentation Changes, Pruritus were assessed in all participants for up to 28 days post-Vaccination.

  Days 0 to 28 post-vaccination

Secondary Outcomes (4)

• Number of Participants With Seroconversion to Homologous ChimeriVax™-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Followed by a Booster Vaccine Dose.

  Month 6 pre- and post-vaccination

• Number of Participants With Seroconversion to Homologous ChimeriVax™-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Followed or Not by a Booster Vaccine Dose at 6 Month.

  Month 12 post-vaccination

• Number of Participants With Seroconversion to Homologous ChimeriVax-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Followed or Not by a Booster Vaccine Dose at 6 Month.

  Month 24 post-vaccination

• Number of Participants Reporting Treatment Emergent Adverse Events Recorded as Possibly, Probably, or Definitely Related to Study Treatment.

  Day 0 up to 28 post-vaccination

Study Arms (2)

Study Group 1: ChimeriVax™-JE Vaccine first, then Placebo

EXPERIMENTAL

Participants received ChimeriVax™-JE on Day 0 and ChimeriVax diluent on Day 28

Biological: Live attenuated Japanese encephalitis virus, then ChimeriVax diluent

Study Group 2: Placebo first, then ChimeriVax™-JE Vaccine

EXPERIMENTAL

Participants received ChimeriVax diluent on Day 0 and ChimeriVax™-JE on Day 28.

Biological: ChimeriVax diluent, then Live attenuated Japanese encephalitis virus

Interventions

Live attenuated Japanese encephalitis virus, then ChimeriVax diluent BIOLOGICAL

ChimeriVax™-JE, 0.5 mL subcutaneous on Day 0; ChimeriVax diluent 0.5 mL subcutaneous on Day 28

Also known as: ChimeriVax™-JE

Study Group 1: ChimeriVax™-JE Vaccine first, then Placebo

ChimeriVax diluent, then Live attenuated Japanese encephalitis virus BIOLOGICAL

ChimeriVax diluent, 0.5 mL subcutaneous on Day 0 and ChimeriVax™-JE, 0.5 mL subcutaneous on Day 28.

Also known as: ChimeriVax™-JE

Study Group 2: Placebo first, then ChimeriVax™-JE Vaccine

Eligibility Criteria

• Age: 18 Years - 54 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• At entry:
• All aspects of the protocol explained and written informed consent obtained from the subject.
• Aged ≥ 18 to \< 55 years.
• In good general health, without significant medical history, physical examination findings, or clinically significant abnormal laboratory results.
• Subject must be available for the study duration, including all planned follow-up visits.
• Has the subject agreed to take the following precautions to avoid insect bites for 7 days following vaccination: (a) wear long-sleeved shirts and trousers?; (b) apply N,N-Diethyl-meta-toluamide (DEET)-containing insect repellents?; (c) Sleep in screened enclosures?
• For female subjects of childbearing potential: Negative serum pregnancy tests. An efficacious hormonal (i.e., oral, implantable or injectable) or barrier method of birth control must be used at least 1 month before Screening and Month 6 and at least 1 month after Day 28 and Month 6. These subjects will sign an agreement that birth control will be practised during the specified periods and will specify the method used. Female subjects unable to bear children must have this documented (e.g., tubal ligation or hysterectomy).
• For long-term immunogenicity follow-up period:
• Subject received an initial dose of ChimeriVax™-JE, has a baseline (Day 0) sample and at least one post-vaccination evaluable serological specimen for antibody analysis.
• All aspects of the Long-term Immunogenicity Follow-up Period explained and updated written informed consent obtained from the subject.
• In good general health, without significant medical history that may affect the efficacy endpoints or the ability to take blood samples.

You may not qualify if:

• Known or suspected immunodeficiency (e.g., human immunodeficiency virus \[HIV\] infection, primary immunodeficiency disorder, leukemia, lymphoma), use of immunosuppressive or antineoplastic drugs (corticosteroids \> 10 mg prednisone, or equivalent, for more than 14 days in the last three months).
• Clinically significant abnormalities on laboratory assessment.
• Serious adverse reactions characterised by urticaria or angioedema to a prior vaccine.
• Transfusion of blood or treatment with any blood product, including intramuscular or intravenous serum globulin within six months of the Screening Visit or up to Day 56.
• Administration of another vaccine within 30 days preceding the screening visit or up to Day 56 (these subjects will be rescheduled for vaccination at a later date).
• Physical examination indicating any clinically significant medical condition.
• Body temperature \>38.1°C (100.6°F) or acute illness within 3 days prior to inoculation (subject may be rescheduled).
• Intention to travel out of the area prior to the study visit on Day 56.
• Seropositive to hepatitis C virus (HCV) or HIV or positive for hepatitis B (HBV) (antigen).
• Lactation or intended pregnancy in female subjects.
• Excessive alcohol consumption, drug abuse, significant psychiatric illness.
• A known or suspected physiological or structural condition that compromises the integrity of the blood-brain barrier (e.g., significant hypertensive cerebrovascular disease, trauma, ischemia, infection, inflammation of the brain).
• For long-term immunogenicity follow-up period:
• History of Yellow Fever or out of study JE vaccination or known flavivirus infection since receiving ChimeriVax™-JE vaccination on Day 0 or Day 28 (during double-blind treatment period of the study). Yellow Fever/JE vaccination or flavivirus infection will be determined by history (interview of subject) and/or by reviewing the subject's medical records. Please note subjects who were flavivirus positive at Day 0 will be allowed to enrol on the study.
• Participation in another JE clinical study.

Sponsors & Collaborators

• Sanofi: lead

Study Sites (1)

Unknown Facility

Enoggera, Queensland, 4051, Australia

Location

Related Publications (1)

• Nasveld PE, Ebringer A, Elmes N, Bennett S, Yoksan S, Aaskov J, McCarthy K, Kanesa-thasan N, Meric C, Reid M. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults. Hum Vaccin. 2010 Dec;6(12):1038-46. doi: 10.4161/hv.6.12.13057. Epub 2010 Dec 1.

  PMID: 21150279 RESULT

Related Links

• Related Info

MeSH Terms

Conditions

Encephalitis; Encephalitis, Japanese

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neuroinflammatory Diseases; Encephalitis, Arbovirus; Encephalitis, Viral; Central Nervous System Viral Diseases; Central Nervous System Infections; Infections; Infectious Encephalitis; Arbovirus Infections; Vector Borne Diseases; Mosquito-Borne Diseases; Virus Diseases; RNA Virus Infections; Flavivirus Infections; Flaviviridae Infections

Results Point of Contact

• Title: Medical Director
• Organization: Sanofi Pasteur Inc.

RegistryContactUs@sanofipasteur.com

Study Officials

• Medical Director

  Sanofi Pasteur Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 21, 2009
• First Posted: September 22, 2009
• Study Start: April 1, 2003
• Primary Completion: June 1, 2004
• Study Completion: February 1, 2008
• Last Updated: July 16, 2012
• Results First Posted: April 29, 2011

Record last verified: 2012-07

Locations

AU (1)